전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved189 programs
ADCCurated CoreFDAstaleRochevedotin, rituximab, cycloph…Phase 3

Polatuzumab Vedotin (Polatuzumab Vedotin)

Large B-Cell Lymphoma · FRα

#FR#ADC#Phase3#FDA-approved#BioJungboMoa-pick+5
Trials 91Status Recruiting
AntibodyCurated CoreFDARocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
AntibodyCurated CoreFDAGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
ADCLimited DataFDAstaleRochePreclinical

Polatuzumab Vedotin-Piiq (Polatuzumab Vedotin-Piiq)

Diffuse Large B-Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Preclinical#FDA-approved#antibody-drug-conjugate+1
Trials 1Status Active
CGTLimited DataGlaxoSmithKlinePhase 1

19 (T2, 19, 19(T2)28z1xx TRAC T cell)

B-Cell Lymphoma; Large B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 340Status Recruiting
ADCStandard DatabasestaleRochevedotin plus rituximab, cyc…Phase 2

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 177Status Discontinued
AntibodyCurated CorestaleRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 153Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Mabthera (Mabthera)

Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 129Status Active
CGTStandard DatabasestaleBioceltech Therapeutics, Ltd.Phase 2

CD19 CAR T cells (CD19 CAR T cells)

Lymphomas Non-Hodgkin's B-Cell; Relapse · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 128Status Recruiting
CGTLimited DatastaleJuventas Cell Therapy Ltd.Phase 1

CD19 CAR-T (CD19 CAR-T)

B-cell Malignancy; B-cell Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 93Status Active
CGTStandard DatabasestaleAbClonPhase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
CGTStandard DatabasestaleGeneplus-Beijing Co. Ltd.Phase 2

natural killer cell infusion (natural killer cell infusion)

Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood B-Lymphoblastic Lymphoma · Recurrent B-Cell Childhood Acute Lymphob

#RecurrentB-CellChildhoodAcuteLym#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 58Status Active
CGTLimited DatastaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTStandard DatabasestaleNational Cancer Institute (NCI)Phase 2

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-CAR PBL)

Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleCRISPR Therapeutics AGPhase 1

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22 CAR (CD22 CAR)

B-ALL; B-cell Non Hodgkin Lymphoma · CD22

#CD22#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
AntibodyLimited DatastaleSeagenPhase 2

Brentuximab (Brentuximab)

Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 51Status Discontinued
AntibodyLimited DatastaleMridula George, MDPhase 2

Retifanlimab (Retifanlimab)

Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#AnatomicStageIVBreastCancerAJCCv+3
Trials 49Status Recruiting

1 / 10 pages

← PreviousNext →